Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150747 · ClinicalTrials.gov registry record
Chlamydia Trachomatis Immunology and Vaccinology Study
A clinical trial, sponsored by Harold Wiesenfeld.
- Completed
- Registry status
- 347
- Enrollment target
NCT01150747: Completed study, sponsored by Harold Wiesenfeld.
NCT01150747 is a clinical trial that has completed, run by Harold Wiesenfeld. The registered enrollment target is 347 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01150747 has completed, sponsored by Harold Wiesenfeld.
- COMPLETED
- Registry status
- 347 participants
- Enrollment target
Study Summary
The primary objective is to prospectively follow 200 women with or at risk of cervicitis to determine the chlamydia-specific cellular responses that correlate with protection against incident infection. The hypothesis is that a positive IFN-y response by peripheral CD4+ T cells responding to stimulation with HSP60 will be significantly associated with protection from incident C. trachomatis infection.
Interventions
- DRUG Azithromycin
- DRUG ceftriaxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-08 |
What the finished NCT01150747 record still lists
NCT01150747 is an observational study that tracks outcomes without assigning an intervention. The registered 347 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Azithromycin is the first listed.
NCT01150747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01150747 about?
NCT01150747 is a clinical study titled "Chlamydia Trachomatis Immunology and Vaccinology Study". The primary objective is to prospectively follow 200 women with or at risk of cervicitis to determine the chlamydia-specific cellular responses that correlate with protection against incident infection. The hypothesis is that a positive IFN-y response by peripheral CD4+ T cells responding to stimula...
What is the current status of trial NCT01150747?
This trial is currently completed. The enrollment target is 347 participants. The study started on 2011-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01150747?
The interventions under investigation include: Azithromycin (DRUG), ceftriaxone (DRUG).
Who is sponsoring clinical trial NCT01150747?
This trial is sponsored by Harold Wiesenfeld, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
- NCT04877522 · 347 participants · Phase 4
Asciminib Roll-over Study
- NCT05834660 · 347 participants · NA
SAFETY-A for Promoting Equity in Suicide Prevention Outcomes in Schools
- NCT06963827 · 347 participants · Phase 3
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia